Antonio Giordano, MD PhD (@antgiorda) ranks #21 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 6 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: SERENA-6, VIKTORIA-1, VERITAC-2 (vepdegestrant). CMS Open Payments lists $23,046 in 2025 general payments.
At a Glance
- 3 posts naming a trial in 2026
- 3 trials discussed by name
- Breast Cancer: US #21 · 6 physicians engaged
- Presented at ESMO 2026 in 2026
- CMS Open Payments lists $23,046 in 2025 general payments.
This Month
What Antonio Giordano, MD PhD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Antonio Giordano, MD PhD
Physicians who reposted Antonio Giordano, MD PhD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #21 | — | 6 | 6 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Antonio Giordano, MD PhD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ESMO 2026 · Proffered paperFOURLIGHT-1: Efficacy and Safety of Atirmociclib + Fulvestrant in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer Who Progressed on Prior CDK4/6 Inhibitor in a Randomized Phase 2 StudySource: @DFCI_BreastOnc on X ↗
What Colleagues Are Saying About Antonio Giordano, MD PhD
2026 posts by fellow physicians that mention @antgiorda, quoted word for word.
Very promising randomized results with the CDK4 selective inhibitor atirmociclib presented by @antgiorda. Next gen CDKs are here! #ESMO26 #ESMOAmbassadors https://t.co/XuIiabKA5H https://t.co/YuDTbHahRg
FourLight-1 presented by @antgiorda at #ESMO26 Atirmociclib + fulvestrant improved median PFS vs investigator’s choice after CDK4/6i progression in HR+/HER2− metastatic breast cancer (9.4 vs 6.6 months; HR 0.60; p=0.0007) @DFCI_BreastOnc @OncoAlert https://t.co/Izo75JxXQx
Oral abstract #BreastCancer session at #ESMO26: phase 2 results with the #CDK4 inhibitor #atirmociclib in addition to #fulvestrant presented by the great @antgiorda 🇮🇹 in patients with endocrine-resistant disease @OncoAlert @myESMO @Annals_Oncology https://t.co/oW7cVBPERH
FOURLIGHT-1 #ESMO26 @antgiorda Atirmociclib + fulvestrant significantly improved PFS vs investigator’s choice in HR+/HER2− metastatic breast cancer after CDK4/6i (9.4 vs 6.6 months; HR 0.60). CBR was higher (61.9% vs 46.0%), with manageable safety, although grade ≥3 AEs were more frequent.
Great to see my longtime friend @antgiorda present FOURLIGHT-1 at #ESMO26: atirmociclib + fulvestrant improved PFS vs investigator's choice after prior CDK4/6 (9.4 vs 6.6 mo, HR 0.60). Encouraging data after CDK4/6. #ESMOAmbassadors @myESMO https://t.co/beBzI9zSQZ
At #ESMO26 Proffered Paper 2️⃣ on #breastcancer @antgiorda presents FOURLIGHT-1 Atirmociclib (CDK4i) + fulvestrant in HR+ aBC after PD to CDK4/6i ⬆️ PFS (delta of 3 months) Ongoing ph3 trial of atirmociclib in 1 line @OncoAlert https://t.co/PJlzwUgyDS
Trials Antonio Giordano, MD PhD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| SERENA-6 | 2 | #23 of 39 | Sep 4, 2026 |
| VIKTORIA-1 | 1 | #8 of 23 | Jun 2, 2026 |
| VERITAC-2 (vepdegestrant) | 1 | #13 of 18 | May 1, 2026 |
Antonio Giordano, MD PhD on SERENA-6
FDA granted accelerated approval to Etcamah (camizestrant) + CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of HR+HER2- MBC upon detection of ESR1 mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on ctDNA (SERENA-6)
In this time of oral serd controversy (SERENA-6) FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer - The ASCO Post https://t.co/Kf11KqnnUB
Antonio Giordano, MD PhD on VIKTORIA-1
VIKTORIA-1 met its primary endpoint in PI3K-mut HR+/HER2- PFS n=155 Geda+Palbo+FUL 11.1m (HR 0.5;0.37-0.68) n=55 Geda+FUL 11.3m (HR 0.51;0.33-0.79) n=155 SOC Alpelisib+FUL 5.6m Triplet vs doublet vs ALP saf: G3 hyperglycemia 2.6%, 0%, 13.8% G3 stoma 16.3% 5.8% 5.3% #ASCO26
Antonio Giordano, MD PhD on VERITAC-2 (vepdegestrant)
In this time of oral serd controversy (SERENA-6) FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer - The ASCO Post https://t.co/Kf11KqnnUB
Antonio Giordano, MD PhD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
FDA approves gedatolisib in combination with fulvestrant, with or without palbociclib, for adults with HR+/HER2-locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy
https://t.co/8J0P9yNZ2p
We celebrate Dana Farber achievements at #ASCO26. Very proud of our new president elect @EMittendorfMD involved in the #firstdance @DanaFarber ASCO party event with mitico napoletano @DrChoueiri https://t.co/VMqXhMye32
Next serious unmet need in HR+/Her2- early breast cancer. How to rescue patients with MRD+ disease? #ESMO26 https://t.co/QG5pxihvFU
MD/PhD program friends - lifetime friends. #ESMO26 https://t.co/vyryi0m7mR
Industry Payments
CMS Open Payments · 2025 general payments
$23,046 across 24 payments